BioCorRx acquires intellectual property for drug administration

Patent application covers solid implant formulation for drug delivery

ANAHEIM, CA, November 22, 2021 (GLOBE NEWSWIRE) – via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), developer and provider of innovative treatment programs for drug addiction and related disorders, today announced that the company has acquired a patent application from Calista Therapeutics. The current application, 17/465,748, has been filed with the United States Patent and Trademark Office (USPTO) covering solid implant formulation for drug delivery. This intellectual property complements the Company’s current intellectual property portfolio and may be used to improve current formulations of naltrexone owned by the Company or licensed to third parties for use with other molecules for which implant formulations. solids are desired.

Lourdes Felix, CEO, CFO and Director of BioCorRx Inc., said: “We are delighted to add this new application to our portfolio, which may improve some aspects of solid implant drug delivery. We believe this intellectual property adds value to our portfolio and we plan to explore its uses with our current formulations as well as others in the area of ​​implantable drug delivery.

About BioCorRx

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company providing a unique approach to the treatment of drug addiction and other related disorders. Beat Addiction Recovery is a substance use disorder recovery program that typically includes BioCorRx’s proprietary Cognitive Behavioral Therapy (CBT) modules, as well as peer support via a mobile app, as well as medications prescribed by an independent attending physician at their discretion. The UnCraveRx® Weight Loss Program is also a drug-assisted weight loss program that includes access to on-demand wellness specialists: nutritionists, fitness experts and expert personal support. behviour ; please visit for more information on UnCraveRx®. The Company also controls BioCorRx Pharmaceuticals, a clinical-stage drug development subsidiary currently seeking FDA approval for BICX104, an implantable naltrexone lozenge for the treatment of alcohol and alcohol use disorders. opioids. For more information about BICX and its subsidiaries, please visit

Safe Harbor Declaration

The information contained in this press release includes forward-looking statements. These forward-looking statements are generally identified by the words “believe”, “plan”, “estimate”, “become”, “plan”, “will” and similar expressions. These forward-looking statements involve both known and unknown information. risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from forward-looking statements, which reflect the views of the management of the Company only as of the date hereof.

BioCorRx Inc.
[email protected]
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
[email protected]

Media contact:
CMW Media
(858) 264-6600
[email protected]

Source link

Comments are closed.